Fig. 3: UNC2025 sensitizes Ewing sarcoma cells to SN-38 in vitro and irinotecan in vivo.
From: Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma
a–h Representative heatmaps for cell viability (upper panels) and combination index (CI, lower panels) in MHH-ES-1 cells treated with indicated doses of UNC2025 (X-axis) with SN-38 (Y-axis) for 2 days. Please refer to the method section for more details. The heatmaps presented are representative data from biological triplicates. Cell viability was measured by Cell Titer-Glo assays and normalized to DMSO treatment. The color scale bar indicates % of survived cells, where 1.0 represents 100%. i Tumor volume measurements at indicated days post-injection with indicated compounds injected at the indicated days. Both irinotecan (10 mg/kg) and UNC2025 (10 mg/kg) were injected via IP. Error bars were calculated as mean ± SD, n = 7 tumors. p values are calculated as indicated (two-way ANOVA followed by Tukey multiple comparison test). j Isolated tumors from (i) and weighed in (k). Error bars were calculated as mean ± SD, n = 7 tumors. p values are calculated as indicated (two-tailed student’s t-test).
